Navigation Links
Lifeline Biotechnologies and Depository Trust Company
Date:9/30/2011

RENO, Nev., Sept. 30, 2011 /PRNewswire/ -- Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) announced today that the Company continues efforts to reestablish DTC services.

Jim Holmes, Lifeline's CEO said "While our efforts have continued to reestablish DTC's services to the Company we have not been successful.  We now are considering alternatives should the circumstances not change.

The value of Lifeline is not reflected in the current lack of liquidity (low per share market price and low daily volume of shares traded).  Lifeline's investment in First Warning Systems has not diminished; in fact, First Warning's value has appreciated as established milestones have been achieved.  Our focus in First Warning is preparation for the final round of clinical trials estimated to commence in the latter half of 2012.   At this time, our best estimate for trial completion is late 2013. The trails must be successfully completed before our FDA medical device marketing application is submitted in the U.S."

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

CONTACT: Lifeline Biotechnologies, Inc.
Jim Holmes, 775-326-9614    Email: Jholmes@lbti.com    website: www.lbti.com


'/>"/>
SOURCE Lifeline Biotechnologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
2. Lifeline Skin Care™ Selects Click Here, Inc., Richards Partners
3. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
4. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
5. Benjamin Custodio Joins Millennium Biotechnologies to Expand International Sales
6. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
7. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
8. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
9. Andre Marion Joins Microchip Biotechnologies Board of Directors
10. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
11. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... ... Financial Services (NYS DFS) cybersecurity regulations have transitioned into full force ... organizations operating in the state (“Covered Entities”) to conduct an annual, professional, ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... to produce biochar, briquettes, and torrefied wood is the topic of a ... To characterize the potential economic viability of transportable biomass conversion facilities for producing ...
(Date:9/18/2017)... , Sept. 18, 2017   Montrium , a growing leader ... exciting new partnership with a groundbreaking non-profit research organization, Multidisciplinary ... ... psychotherapy studies for PTSD ... recently granted Breakthrough Therapy Designation to MDMA for the treatment of ...
(Date:9/17/2017)... ... September 17, 2017 , ... GeneOne Life ... of Food and Drug Safety (KMFDS) for an Investigational New Drug application for ... Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents the second clinical trial ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):